The estimated Net Worth of Ventures Fund Iv General Pa... is at least $219 Thousand dollars as of 19 March 2021. Ventures Pa owns over 210,000 units of Rubius Therapeutics Inc stock worth over $218,597 and over the last 4 years Ventures sold RUBY stock worth over $0.
Ventures has made over 1 trades of the Rubius Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Ventures bought 210,000 units of RUBY stock worth $6,090,000 on 19 March 2021.
The largest trade Ventures's ever made was buying 210,000 units of Rubius Therapeutics Inc stock on 19 March 2021 worth over $6,090,000. On average, Ventures trades about 210,000 units every 0 days since 2021. As of 19 March 2021 Ventures still owns at least 2,633,703 units of Rubius Therapeutics Inc stock.
You can see the complete history of Ventures Pa stock trades at the bottom of the page.
Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz, and Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.
developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.
Rubius Therapeutics Inc executives and other stock owners filed with the SEC include: